When given as a second- or third-line therapy, BeiGene’s tislelizumab is superior to docetaxel at prolonging the survival of people with locally advanced or metastatic non-small cell lung cancer (NSCLC), whose disease progressed while receiving platinum-based chemotherapy. Additionally, tislelizumab had a favorable safety profile that was consistent with that of previous studies, and its use did not cause any new unexpected side effects. These are the main findings of a planned interim analysis recommended by…
You must be logged in to read/download the full post.
The post Tislelizumab Safely Prolongs Survival in Advanced Lung Cancer Patients, Interim Data Show appeared first on BioNewsFeeds.